Skip to main
DHR

Danaher (DHR) Stock Forecast & Price Target

Danaher (DHR) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Danaher is well-positioned to continue its strong performance with a solid portfolio of high-quality products, a diverse revenue stream, and a focus on continuous improvement. Although there are potential risks such as slow recovery in bioprocess equipment demand and challenges in the Chinese diagnostic market, the company's strong Q4 respiratory contribution, updated revenue growth expectations, and positive long-term outlook for their bioprocessing franchise indicate potential for continued growth in the future. Furthermore, their culture of continuous improvement and efficient business system are key strengths that will contribute to the company's success. Overall, Danaher is a strong company with a positive outlook for the future.

Bears say

Danaher is facing challenges in their life sciences and diagnostics divisions, including slower than expected growth in their biotechnology segment and delays in large shipments for programs at commercial customers. In addition, there is uncertainty in the industry with other players performing well and increasing competition, which may affect Danaher's sales processes. However, they have shown strong performance in their life sciences segment and have room for growth with potential acquisitions. There is also potential for growth in their bioprocess business, but there are risks associated with this. The company is making efforts towards sustainable practices and has a mixed track record for acquisitions. Overall, the company's growth potential is uncertain, and there are risks and challenges that may hinder their future performance.

Danaher (DHR) has been analyzed by 18 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Danaher (DHR) Forecast

Analysts have given Danaher (DHR) a Buy based on their latest research and market trends.

According to 18 analysts, Danaher (DHR) has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $230.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $230.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Danaher (DHR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.